November 2015: SMC decisions
The Scottish Medicines Consortium has accepted the following medicines for use in NHS Scotland: atazanavir and cobicistat (Evotaz; Bristol-Myers Squibb); edoxaban (Lixiana; Daiichi Sankyo), for two separate indications; pembrolizumab (Keytruda; Merck Sharp and Dohme), as monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults previously untreated with ipilimumab; tiotropium/olodaterol (Spiolto Respimat; Boehringer Ingelheim); and triamcinolone hexacetonide (Intrapharm).
Bevacizumab (Avastin; Roche) and raltegravir chewable tablets and granules for oral suspension (Isentress; Merck Sharp and Dohme) have been accepted for restricted use.
Everolimus (Certican; Novartis), pembrolizumab (Keytruda; Merck Sharp and Dohme), as monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults previously treated with ipilimumab, and regorafenib (Stivarga; Bayer) are not recommended for use in NHS Scotland.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20200070
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com